Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/MaxCyte, Inc./ 10-K

Annual Report · 10-K

MaxCyte, Inc.

MXCTNASDAQEQUITYCurrent

Annual Report

Filed Mar 11, 2025Accepted Mar 11, 2025, 5:05 PM EDTCIK 1287098Accession 0001558370-25-002721
View company →Permanent SEC source ↗
Share

Company context

At MaxCyte®, we are committed to building better cells together. As a leading cell engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Current securities

MXCTNASDAQ · EQUITY · Current
Historical securities (1)
MAXCOTC · EQUITY · Historical · closed Jul 30, 2021

Recent company filings

  1. 10-Q filingNov 10, 2026
  2. Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Regulation FD DisclosureNov 10, 2026
  3. Results of Operations and Financial ConditionOct 14, 2026
  4. 10-Q filingAug 13, 2026
  5. Results of Operations and Financial Condition · Regulation FD DisclosureAug 12, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.